Opendata, web and dolomites

kINPen

Developing a high-innovative portable cold plasma device for efficient healing of chronic wounds in veterinary medicine

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 kINPen project word cloud

Explore the words cloud of the kINPen project. It provides you a very rough idea of what is the project "kINPen" about.

18    inflammatory    gas    regional    turnover    revenues    country    medical    species    overconsumption    farm    million    antifungal    effect    sustainable    pharmacological    share    forming    600    antibiotic    antimicrobial    months    costumers    led    wellbeing    safe    presenting    efficient    wound    microorganisms    feeling    time    antiviral    ionized    50    multidrug    uv    segments    network    revolutionize    infection    unpleasant    ultrasound    suppliers    advantages    investment    110    reachable    bacteria    radiation    opportunity    kinpen    treatments    uses    return    animals    surface    neoplas    electrons    pet    portable    commercialization    healing    health    obtaining    calculated    manoeuvrable    sales    vet    antibiotics    excited    stimulation    100    electromagnetic    innovative    radicals    accelerates    technologies    device    price    ions    physiological    area    wounds    first    farming    equals    veterinary    approximate    chronic    rising    950    resistance    successfully    ca    plasma    fungi    900    reg    laser    cold    organic    urgently    market    animal    electrical    microorganism    anti    generate    treatment    constitutes    stimulates    resistant   

Project "kINPen" data sheet

The following table provides information about the project.

Coordinator
NEOPLAS GMBH 

Organization address
address: WALTHER RATHENAU STRASSE 49A
city: GREIFSWALD
postcode: 17489
website: www.neoplas.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website https://www.neoplas.eu/en/veterinarymedicine.html
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2019-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NEOPLAS GMBH DE (GREIFSWALD) coordinator 50˙000.00

Map

 Project objective

The veterinary sector urgently needs to revolutionize their treatment methods in order to solve the present antibiotic overconsumption and related growing resistance. This constitutes an important market opportunity for new technologies. Current non-pharmacological infection treatments such as ultrasound, electrical stimulation, laser or LED, are less efficient, given their cost, unpleasant feeling, treatment-time or required area. Therefore, neoplas GmbH successfully developed kINPen®VET, a non-pharmacological, high-innovative and portable cold plasma device for efficient healing of chronic wounds in farm and pet animals. It stimulates and accelerates physiological wound healing and is highly effective against typical wound bacteria, multidrug-resistant microorganisms and fungi, obtaining antiviral, antimicrobial, antifungal and anti-inflammatory effects on the treated surface without the need of antibiotics or developing microorganism resistance. It is based on cold plasma and uses the advantages of the Plasma Effect (ionized gas, electrons and ions, as well as radicals, excited species, UV radiation and electromagnetic fields). KINPen®VET will provide a 100% safe and manoeuvrable device, leading to a more cost-effective and sustainable veterinary medical treatment. kINPen®VET’s commercialization will generate high revenues in the targeted market segments of animal health and wellbeing and organic animal farming (market share 50%). This equals to an approximate number of more than 110.000 systems presenting a turnover of €950 million only in Europe. This ambitious target is reachable by forming a European network of regional suppliers, representatives and costumers in each targeted country. The production costs have been calculated with 5.900 €/ unit in the first 3 years and with a rising production the costs will be reduced to ca. 4.600 €/unit. The sales price is targeted with 8.900 €/unit and will allow a calculated return on investment in under 18 months.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "KINPEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "KINPEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IRMELI (2019)

AI-BASED BROKERING TECHNOLOGY PLATFORM TO FIND THE PERFECT MATCH BETWEEN THE CUSTOMER AND BANK

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More